About DiagNodus


Summary
History
Progress
Partners

 

Latest News

June 2014: Preliminary results of DiagNodus Pilot Clinical Trial presented at the 2014 Annual Meeting of the British Society of Gastroenterology

October 2014: Pilot Clinical Trial of the DiagNodus test for IBD successfully completed

December 2014: Pilot Trial results show excellent performance of the DiagNodus test for IBD detection


May 2015: Second patent of DiagNodus published


October 2015: Second peer-reviewed paper describing Pilot Trial results accepted for publication

October 2015: Scientific Advisory Board of DiagNodus formed

 


 

About DiagNodus

Company Summary

DiagNodus Ltd is a medical diagnostics company which is pioneering the development of novel non-invasive methods of biological material collection and testing for colorectal disease detection. Producing patient-friendly highly sensitive diagnostic solutions is the principal goal of the company.

DiagNodus devices will provide simple and reliable tools for diagnosis, monitoring and treatment efficiency assessment in the area of inflammatory bowel disease (IBD). They will also save lives by improving population screening efficiency for colorectal cancer (CRC).

Short History

DiagNodus was founded in April 2011 by a group of scientists with extensive experience in the field of colorectal disease. Their aim was to develop entirely non-invasive methods of diagnosing and monitoring diseases which could be used by patients in their own home.

In 2011 DiagNodus applied for its first patent and established its laboratory at the Babraham Research Campus in Cambridge, UK.

In 2012-14 the company organised and successfully completed its first pilot clinical trial addressing several important clinical endpoints in the area of IBD in collaboration with the Department of Gastroenterology of St George's Hospital in London. In 2013 the company applied for its second patent.

Current Progress

The completed pilot trial has demonstrated excellent acceptance of DiagNodus method by patients and produced highly impressive results on IBD detection and therapy effect monitoring by the new approach. Abundant results of the trial are now being presented at scientific conferences and published in peer-reviewed journals.

The company is now opening Series A funding round required for supporting the development of a family of new point of care tests addressing IBD-related clinical endpoints.

IBD product development and commercialisation now constitutes the main goal of the company, however CRC early diagnosis and screening remains the second major direction of DiagNodus. It is expected that clinical trials addressing CRC-related endpoints will be started in 2016.

Partners

Copan Flock Technologies
St George's Healthcare NHS Trust
Medicys Limited
Marks & Clerk LLP

 

 

 


© DiagNodus 2015. All rights reserved. Terms of Use Policy. Privacy Policy
DiagNodus Ltd Registered in England number: 7600875 VAT Number: 121522366
Registered Office: 280 Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT